Foghorn Therapeutics Inc. FHTX
Set alert
2.08 USD -0.01 -0.48%
At close · Oct 30
2.08 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
2.01 Day range 2.09
1.85 52-week range 7.07
- YTD
- -61.48%
- 1 year
- -51.74%
- Open
- 2.08
- Prev close
- 2.09
- Mkt cap
- 123.52M
- Vol
- 555.61K
- Avg vol
- 721.87K
- EPS
- -0.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.01
- High
- 2.09
- Forward P/E
- -3.12
- Beta
- 3.15
- Short ratio
- 7.62
- Inst. own
- 72.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 7.50
- 200-d avg
- 6.85
- 1y target
- 12.00
2Y chart
Events in this range
- Nov 4, 2024Earnings: -0.31; estimate -0.42; surprise 26.19%
- Dec 16, 2024Rating: Jefferies · Buy → Buy
- Dec 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (113)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 10, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| RSI: Oversold | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| SMA: Bullish | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Mar 6, 2026 | 8 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 5, 2026 | 10 months ago |
| RSI: Overbought | Dec 22, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 18, 2025 | 10 months ago |
| SMA: Bullish | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Dec 16, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 10, 2025 | 10 months ago |
| SMA: Bearish | Dec 9, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 25, 2025 | 11 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| SMA: Bullish | Nov 14, 2025 | 11 months ago |
| SMA: Bullish | Nov 14, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 28, 2025 | 1 year ago |
| SMA: Bearish | Oct 2, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 17, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 29, 2025 | 1 year ago |
| SMA: Bearish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 28, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 22, 2025 | 1 year ago |
| SMA: Bearish | Aug 21, 2025 | 1 year ago |
| SMA: Bearish | Aug 21, 2025 | 1 year ago |
| SMA: Bullish | Aug 20, 2025 | 1 year ago |
| SMA: Bearish | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| SMA: Bearish | Aug 5, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| RSI: Overbought | Jul 28, 2025 | 1 year ago |
| RSI: Overbought | Jul 16, 2025 | 1 year ago |
| RSI: Overbought | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | May 20, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 26, 2025 | 1 year ago |
| RSI: Overbought | Feb 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| RSI: Oversold | Jan 29, 2025 | 1 year ago |
| RSI: Oversold | Jan 16, 2025 | 1 year ago |
| RSI: Oversold | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 31, 2024 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 12, 2024 | 1 year ago |
Key statistics
- Market cap
- 274.07M
- Enterprise value
- 57.42M
- Trailing P/E
- 0.00
- Forward P/E
- -3.12
- PEG ratio
- 0.00
- Price / sales
- 10.74
- Price / book
- 0.00
- EPS (TTM)
- -1.85
- Beta
- 3.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 25.52M
- Revenue growth
- -55.30%
- Free cash flow
- -42.25M
- Total cash
- 267.40M
- Total debt
- 39.07M
- Return on equity
- 0.00%
- Shares outstanding
- 55.59M
- Short % of float
- 2.11%
- 50-day average
- 7.50
- 200-day average
- 6.85
Analyst view
Consensus: buy
Buy
Price target (mean) 12.00 +476.9% upside
Now 2.08
- Target (low)
- 4.00
- Target (mean)
- 12.00
- Target (high)
- 18.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.27333.
Financials — quick view
FHTX Revenue — quarterly 16.07M
FHTX Net income — quarterly -7.19M
FHTX EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.42 | -0.31 | +0.11 | +26.19% |
| Aug 8, 2024 | Jun 1, 2024 | -0.60 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.60 | -0.45 | +0.15 | +25.00% |
| May 6, 2024 | Mar 1, 2024 | -0.55 | — | — | — |
| May 6, 2024 | Mar 1, 2024 | -0.55 | -0.59 | -0.04 | -7.27% |
| Mar 7, 2024 | Dec 1, 2023 | -0.79 | -0.57 | +0.22 | +27.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 16, 2024 | Jefferies | main | Buy | Buy |
| Sep 24, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Sep 3, 2024 | Jefferies | init | — | Buy |
| Aug 19, 2024 | Evercore ISI Group | init | — | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- foghorntx.com
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
- FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
Your note
Sign in to keep a note on FHTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGRESTA SAMUEL M.D. | Officer | Conversion of Exercise of derivative security | Aug 15, 2023 | 0 |
| BELLON STEVEN F | Officer | Sale | Sep 8, 2024 | 101,957 |
| CAVALIE FANNY | Officer | Sale | Mar 10, 2024 | 75,992 |
| COSTA CARLOS FERNANDO | Officer | Conversion of Exercise of derivative security | Sep 22, 2024 | 0 |
| GOTTSCHALK ADRIAN | Chief Executive Officer | Stock Gift | Aug 16, 2023 | 511,704 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 22.80% | 12,674,120 | 62.48M | Sep 29, 2024 |
| FMR, LLC | 11.39% | 6,333,984 | 31.23M | Sep 29, 2024 |
| BVF Inc. | 9.54% | 5,302,000 | 26.14M | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 5.45% | 3,027,886 | 14.93M | Sep 29, 2024 |
| Raymond James & Associates, Inc. | 4.13% | 2,297,319 | 11.33M | Sep 29, 2024 |
| Blackrock Inc. | 3.26% | 1,811,302 | 8.93M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.42% | 1,902,557 | 9.38M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.73% | 962,180 | 4.74M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.11% | 618,263 | 3.05M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.08% | 601,441 | 2.97M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 1.04% | 579,446 | 2.86M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 519,704 | 2.56M | Sep 29, 2024 |